Ticker

RHHBY

Roche

6 catalysts on file

RHHBY

Roche

Phase 3 AI-extracted

divarasib

KRAS G12C non-small cell lung cancer

50d ago Jul 2, 2026

Press release verified 2mo ago

Countdown card →

RHHBY

Hoffmann-La Roche

Phase 3 Estimated

Sefaxersen (RO7434656)

Primary IgA Nephropathy

T-minus 10 days Aug 31, 2026

ClinicalTrials.gov verified 2mo ago

Countdown card →

RHHBY

Hoffmann-La Roche

Phase 3 Estimated

Satralizumab

NMDAR Autoimmune Encephalitis

T-minus 117 days Dec 16, 2026

ClinicalTrials.gov verified 2mo ago

Countdown card →

RHHBY

Hoffmann-La Roche

Phase 3 Estimated

Afimkibart

Moderately to Severely Active Ulcerative Colitis

T-minus 162 days Jan 30, 2027

ClinicalTrials.gov verified 2mo ago

Countdown card →

RHHBY

Hoffmann-La Roche

Phase 3 Estimated

Giredestrant

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

T-minus 182 days Feb 19, 2027

ClinicalTrials.gov verified 2mo ago

Countdown card →

RHHBY

Hoffmann-La Roche

Phase 2 Estimated

Entrectinib

Breast Cancer

T-minus 313 days ~ Jun 30, 2027

ClinicalTrials.gov verified 2mo ago

Countdown card →